Humacyte Stock Today
| HUMA Stock | USD 4.49 0.11 2.51% |
Performance0 of 100
| Odds Of DistressOver 81
|
Humacyte is trading at 4.49 as of the 23rd of November 2024, a 2.51 percent increase since the beginning of the trading day. The stock's open price was 4.38. Humacyte has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Note, on June 14, 2024, Senator Tommy Tuberville of US Senate acquired $15k to $50k worth of Humacyte's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 26th of August 2021 | Category Healthcare | Classification Health Care |
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company was founded in 2004 and is headquartered in Durham, North Carolina. The company has 128.67 M outstanding shares of which 17.25 M shares are currently shorted by private and institutional investors with about 5.35 trading days to cover. More on Humacyte
Moving together with Humacyte Stock
Moving against Humacyte Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Humacyte Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsHumacyte can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Humacyte's financial leverage. It provides some insight into what part of Humacyte's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Humacyte (HUMA) is traded on NASDAQ Exchange in USA. It is located in 2525 East North Carolina Highway 54, Durham, NC, United States, 27713 and employs 183 people. Humacyte is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 577.72 M. Humacyte conducts business under Biotechnology sector and is part of Health Care industry. The entity has 128.67 M outstanding shares of which 17.25 M shares are currently shorted by private and institutional investors with about 5.35 trading days to cover.
Humacyte currently holds about 189.04 M in cash with (73.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.84.
Check Humacyte Probability Of Bankruptcy
Ownership AllocationHumacyte has a total of 128.67 Million outstanding shares. Humacyte secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. On June 14, 2024, Senator Tommy Tuberville of US Senate acquired $15k to $50k worth of Humacyte's common stock.
Check Humacyte Ownership Details
Humacyte Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| D. E. Shaw & Co Lp | 2024-06-30 | 586 K | |
| Monashee Investment Management Llc | 2024-09-30 | 535 K | |
| Marshall Wace Asset Management Ltd | 2024-06-30 | 463.7 K | |
| Lpl Financial Corp | 2024-06-30 | 463.3 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 406.3 K | |
| Private Advisor Group, Llc | 2024-09-30 | 373.1 K | |
| Deerfield Management Co | 2024-06-30 | 322.9 K | |
| Two Sigma Advisers, Llc | 2024-06-30 | 264.3 K | |
| Aqr Capital Management Llc | 2024-06-30 | 256.3 K | |
| Blackrock Inc | 2024-06-30 | 7.1 M | |
| Vanguard Group Inc | 2024-09-30 | 5.1 M |
Humacyte Historical Income Statement
Humacyte Stock Against Markets
Humacyte Corporate Management
| Harold Alterson | Senior Quality | Profile | |
| Sabrina Osborne | Executive People | Profile | |
| Dale Sander | Chief CFO | Profile | |
| William Scheessele | Chief Officer | Profile | |
| Yang MD | Chief Officer | Profile | |
| Shamik MD | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Humacyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Humacyte. If investors know Humacyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Humacyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.34) | Quarterly Revenue Growth (1.00) | Return On Assets (0.53) | Return On Equity (8.51) |
The market value of Humacyte is measured differently than its book value, which is the value of Humacyte that is recorded on the company's balance sheet. Investors also form their own opinion of Humacyte's value that differs from its market value or its book value, called intrinsic value, which is Humacyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Humacyte's market value can be influenced by many factors that don't directly affect Humacyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Humacyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Humacyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Humacyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.